Aldeyra Therapeutics

Focus: Aldeyra Therapeutics is a biotechnology company focused on aldehyde-trap therapies, a specialized platform technology addressing unmet medical needs. The company is based in Lexington, MA and operates at a pre-revenue or early-stage biotech scale.

Ophthalmology Respiratory Infectious Diseases Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Aldeyra Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Aldeyra Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

13 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ADX-629

Ethanol Intoxication

Phase 1/2

Clinical Trials (1)

NCT05487404A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

Phase 1/2

Help build intelligence for Aldeyra Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on novel aldehyde-trap platform technology with differentiated mechanism of action in an emerging therapeutic space
Early-stage biotech environment offers exposure to drug discovery, development, and clinical strategy across multiple functions
Chance to build institutional knowledge and contribute meaningfully during formative company growth phase

Watch Out For

No active clinical trials reported and limited pipeline visibility creates uncertainty around clinical catalysts and value inflection points
Zero current job openings and sparse team size suggest limited near-term hiring and career progression opportunities

Generated by Claude from Aldeyra Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Reproxalap Ophthalmic Solution

Allergic Conjunctivitis

Phase 1/2

Clinical Trials (1)

NCT03660878A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Phase 1/2

Reproxalap Ophthalmic Solution

Conjunctivitis, Allergic

Phase 1/2

Clinical Trials (1)

NCT03709121A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Phase 1/2

Active topical NS2 1% dermatologic cream

Sjögren-Larsson Syndrome

Phase 2

Clinical Trials (1)

NCT02402309A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

Phase 2

NS2 Ophthalmic Drops

Allergic Conjunctivitis

Phase 2

Clinical Trials (1)

NCT02578914A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Phase 2

ADX-102 Ophthalmic Drops

Conjunctivitis, Allergic

Phase 2

Clinical Trials (1)

NCT03012165A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Phase 2

ADX-2191

Retinitis Pigmentosa

Phase 2

Clinical Trials (1)

NCT05392179A Study in Subjects With Retinitis Pigmentosa

Phase 2

Reproxalap Ophthalmic Solution

Dry Eye Syndromes

Phase 2

Clinical Trials (1)

NCT05424549A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Phase 2

ADX-629

Atopic Asthma

Phase 2

Clinical Trials (1)

NCT04728711A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Phase 2

Reproxalap Ophthalmic Solution

Dry Eye

Phase 2

Clinical Trials (1)

NCT05102409An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

Phase 2

ADX-629

Atopic Dermatitis

Phase 2

Clinical Trials (1)

NCT05717920A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Phase 2

ADX-629

Plaque Psoriasis

Phase 2

Clinical Trials (1)

NCT04908514A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Phase 2

ADX-629

Chronic Cough

Phase 2

Clinical Trials (1)

NCT05392192A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Phase 2

Reproxalap Ophthalmic Solution

Dry Eye Syndrome

Phase 2

Clinical Trials (1)

NCT03404115A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Phase 2

ADX-102 Ophthalmic Solution

Dry Eye Syndromes

Phase 2

Clinical Trials (1)

NCT03162783A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Phase 2

ADX-629

Nephrotic Syndrome

Phase 2

Clinical Trials (1)

NCT05599815Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Phase 2

Reproxalap Ophthalmic Solution

Dry Eye

Phase 2

Clinical Trials (1)

NCT03916042A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Phase 2

ADX-629

Alcohol Hepatitis

Phase 2

Clinical Trials (1)

NCT06685692A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

Phase 2

Reproxalap Ophthalmic Solution

Dry Eye

Phase 2

Clinical Trials (1)

NCT04971031A Clinical Trial to Assess Subjects With Dry Eye Disease.

Phase 2

ADX-629

Covid19

Phase 2

Clinical Trials (1)

NCT04847544A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Phase 2

NS2

Non-infectious Anterior Uveitis

Phase 2

Clinical Trials (1)

NCT02406209A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

Phase 2

Reproxalap Ophthalmic Solution

Dry Eye

Phase 2/3

Clinical Trials (1)

NCT04674358The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Phase 2/3

Reproxalap Ophthalmic Solution

Dry Eye Disease

Phase 3

Clinical Trials (1)

NCT06493604A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Phase 3

Reproxalap Ophthalmic Solution

Dry Eye

Phase 3

Clinical Trials (1)

NCT03879863The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Phase 3

Reproxalap Ophthalmic Solution

Allergic Conjunctivitis

Phase 3

Clinical Trials (1)

NCT03494504ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Phase 3

ADX-102 1% Topical Dermal Cream

Sjogren-Larsson Syndrome

Phase 3

Clinical Trials (1)

NCT03445650RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Phase 3

ADX-102 Ophthalmic Solution

Non-infectious Anterior Uveitis

Phase 3

Clinical Trials (1)

NCT03131154SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Phase 3

Reproxalap Ophthalmic Solution

Dry Eye Disease

Phase 3

Clinical Trials (1)

NCT04735393A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Phase 3

Reproxalap Ophthalmic Solution

Dry Eye Disease

Phase 3

Clinical Trials (1)

NCT06389214A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

Phase 3

ICM ADX-2191 injection

Primary Vitreoretinal Lymphoma

Phase 3

Clinical Trials (1)

NCT07402876A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma